Approximately 47% of basal breast tumors are RB1 positive based on higher than average levels of protein expression (Supplementary Fig. 9c), suggesting that this sub-population of TNBC patients could benefit from GLUT1 inhibition. The gene discussed is SLC2A1; the disease is breast neoplasm.